{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:41:10Z","timestamp":1790304070209,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":4912,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1111\/j.1538-7836.2009.03391.x","type":"journal-article","created":{"date-parts":[[2009,7,13]],"date-time":"2009-07-13T07:24:21Z","timestamp":1247469861000},"page":"258-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"S1","title":["Aspirin, 110\u2003years later"],"prefix":"10.1016","volume":"7","author":[{"given":"C.","family":"PATRONO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"ROCCA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0010","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0015","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0020","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0030","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","article-title":"Role of dose-potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0035","doi-asserted-by":"crossref","first-page":"776S","DOI":"10.1378\/chest.08-0685","article-title":"The primary and secondary prevention of coronary artery disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Becker","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0040","doi-asserted-by":"crossref","first-page":"630S","DOI":"10.1378\/chest.08-0720","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Albers","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0045","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpcardio0728","article-title":"Drug insight: aspirin resistance- fact or fashion?","volume":"4","author":"Patrono","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. Implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0060","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.bcp.2007.12.005","article-title":"Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase","volume":"75","author":"Bala","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0065","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0070","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data. Lancet(In press)."},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0085","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2009.03391.x_bb0090","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2009.03391.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622174118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622174118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2009.03391.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:49:07Z","timestamp":1761533347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622174118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":17,"alternative-id":["S1538783622174118"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03391.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin, 110\u2003years later","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03391.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}